Translation

PATENT COOPERATION TREATY



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 0000053862	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)					
International application No. PCT/EP2003/009102	International filing date (day/n 18 August 2003 (18.0		Priority date (day/month/year) 20 August 2002 (20.08.2002)			
International Patent Classification (IPC) or n C12P23/00, C12N15/82, C12N9	national classification and IPC	0.2003)	20 August 2002 (20.00.2002)			
Applicant	SUNGENE GMBH & C	O.KGAA				
2. This REPORT consists of a total of This report is also accompan amended and are the basis fo 70.16 and Section 607 of the	ccording to Article 36. 6sheets, including the day ANNEXES, i.e., sheets of the control	ng this cover s f the descriptioning rectification	national Preliminary Examining Authority sheet. on, claims and/or drawings which have been thions made before this Authority (see Rule			
3. This report contains indications relating to the following items: I Basis of the report II Priority III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV Lack of unity of invention V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI Certain documents cited VII Certain defects in the international application VIII Certain observations on the international application						
Date of submission of the demand 18 March 2004 (18.03.2004)		Date of completion of this report 03 November 2004 (03.11.2004)				
Name and mailing address of the IPEA/EP	Autho	rized officer				
Facsimile No.	Telent	one No.				

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP2003/009102

I. Basi	I. Basis of the report							
1. Wit	h regard to	the elements of the international application:*	_					
	the international application as originally filed							
	the des	the description:						
	pages							
	pages							
1	pages	, filed with the letter of						
	the clai							
	J							
ł	pages pages	1-100 , as originally filed						
	pages	, as amended (together with any statement under Article 19						
	pages	, filed with the demand	1					
	 I	, filed with the letter of	-					
	the drav							
ł	pages		1					
1	pages	, filed with the demand	l					
	pages	, filed with the letter of	_					
	the seque	nce listing part of the description:						
	pages	1-244 , as originally filed	1					
	pages	, filed with the demand						
l	pages	, filed with the letter of	_					
me	the lan	to the language, all the elements marked above were available or furnished to this Authority in the language in which all application was filed, unless otherwise indicated under this item. Its were available or furnished to this Authority in the following language which is: guage of a translation furnished for the purposes of international search (under Rule 23.1(b)). guage of publication of the international application (under Rule 48.3(b)). guage of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/).	:					
3. Wi	uminary e	to any nucleotide and/or amino acid sequence disclosed in the international application, the international xamination was carried out on the basis of the sequence listing: led in the international application in written form.	1					
	7	gether with the international application in computer readable form.						
	1	ed subsequently to this Authority in written form.						
	1	ed subsequently to this Authority in computer readable form.						
	The st	atement that the subsequently furnished written sequence listing does not go beyond the disclosure in the tional application as filed has been furnished.	>					
	The st been ft	atement that the information recorded in computer readable form is identical to the written sequence listing has	5					
4.	The an	nendments have resulted in the cancellation of:						
		the description, pages						
	1 7	the claims, Nos.						
		the drawings, sheets/fig						
5. [This rep	port has been established as if (some of) the amendments had not been made, since they have been considered to go the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**	>					
1111	lacement : this report ! 70.17).	sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16	5					
** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.								

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/E0 30/09102

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

1.	Statement	g such statement		
	Novelty (N)	Claims	2, 10, 11, 13, 17-67, 69, 70, 74, 76-85, 91-95	YES
		Claims	1, 3-9 12, 14-16, 68, 71-73, 75, 86-90, 96-100	NO
	Inventive step (IS)	Claims		YES
		Claims	1-100	NO
	Industrial applicability (IA)	Claims	1-100	YES
		Claims		NO

- 2. Citations and explanations
 - 1. Reference is made to the following documents:
 - D1: WO 03/080849 A (BALL HORTICULTURAL COMPANY)
 2 October 2003
 - D2: WO 98/18910 A (YISSUM RES DEV CO (IL))
 7 May 1998
 - D3: DATABSE UNITPROT [Online] 1 March 2002
 (2002-03-01), KANEKO, T. ET AL.: "Beta-carotene ketolase", found in EBI accession no. Q8YSA0,
 Database accession no. Q8YSA0
 - D4: WO 00/32788 A (HANSEN) 8 June 2000
 - D5: WO 99/07867 a (CALGENE LLC)
 - 18 February 1999
 - D6: WO 00/61764 A (BASF AG)
 - 19 October 2000
 - D7: WO 99/63055 A (UNIV MARYLAND (US))
 - 9 December 1999
 - D8: WO 99/61652 A (UNIV MARYLAND)
 - 2 December 1999.

/...

International application No. PCT/E0 30/09102

- Novelty and inventive step (PCT Article 33(2) and (3)):
- 2.1 Document D1, classified as an E document in the search report, has been disregarded for the purpose of the examination since the priority of the application was assumed to be valid.
- 2.2 Document D2 discloses (see pages 18-20, 28-29, 31-32 and 38-41) transgenic plants that express betacarotene oxygenase (ketolase) from Haematococcus pluvialis in chromoplasts and, hence, in flowers also (see D2, claim 68 and page 39), using a construct that is identical to one of the constructs according to the application, in other words that is identical to a chromoplast promoter and a chromoplast transit peptide.

In consequence, D2 is prejudicial to the novelty of claims 1, 3-9, 12, 14-16, 68, 71-73, 75, 86-90 and 96-100.

2.3 An inventive step can be acknowledged if the subject matter of an (independent) claim solves a technical problem in a non-obvious manner.

Therefore, the following conditions must be satisfied:

- i) there must be a problem;
- said problem must be solved for the entire
 scope of the claim;

/ . . .

- iii) all the features that contribute to the
 solution must be contained in the
 independent claim; and
- iv) the solution must not be obvious.

The problem addressed by the present invention (see page 2, lines 14-20) consists in developing an alternative method for producing ketocarotenoids by plant cultivation and developing further ketocarotenoid-producing transgenic plants, said plants having **optimised** properties - for example a higher ketocarotenoid content.

In claim 1, a system for solving said problem is described in very general terms. Although a number of embodiments are defined in greater detail in the description, the applicant has failed to show that these embodiments, or at least one thereof, also actually solve(s) the problem, that is to say have (has) optimised properties relative to the prior art - for example increased ketocarotenoid content or improved purity. Moreover, there are no examples relating to the subject matter of claims 2 and 29-61. Thus, conditions ii) and iii) are not satisfied and an inventive step cannot be acknowledged; in other words, it is not possible to establish whether or not an inventive step is involved until conditions ii) and iii) are satisfied.

2.4 Irrespective of the above objections, the applicant is advised that, even were the independent claims to be rendered novel by combination with a (novel)

/...

International application No. PCT/E0 30/09102

dependent claim, said combination would still not be inventive, since dependent claims 2, 10, 11, 13, 17-67, 69, 75 and 76-85 contain no features which, combined with the features of any claim to which they refer, meet the PCT requirements for inventive step (see documents D3-D8 and the corresponding passages of text cited in the search report).

- Clarity (PCT Article 6)
- 3.1 The term "ketolase", used in the claims, is vague and lacks clarity, leaving the reader uncertain as to the meaning of the technical feature in question. The term used by a person skilled in the art is "beta-C4-4-oxygenase" or "4-4'-oxygenase".
- 3.2 The broadest claim is claim 12, not claim 1.